ET-traps as a potential treatment for COVID-19

WHO, 2020 Channappanavar, 2019, IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes, J Clin Invest, 130, 3625, 10.1172/JCI126363 Jose, 2020, COVID-19 cytokine storm: the interplay between inflammation and coagulation, Lancet Respir Med, 10.1016/S2213-2600(20)30216-2 Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 Sarah Freeman, 2014, Endothelin-1 and its role in the pathogenesis of infectious diseases, Life Sci, 118, 110, 10.1016/j.lfs.2014.04.021 Jain, 2017, Creating a Soluble Binder to Endothelin-1 based on the natural ligand binding domains of the endothelin-1 (G-protein-coupled) receptor, Int J Pept Res Ther, 107 Arjun, 2018, Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes, J Diabetes Metab Disord Jain, 2019, In vivo studies demonstrate that endothelin-1 traps are a potential therapy for type I diabetes, J Diabetes Metab Disord, 133, 10.1007/s40200-019-00400-7 Fagan, 2001, Role of endothelin-1 in lung disease, Respir Res, 2, 90, 10.1186/rr44 Swigris, 2010, The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis, BioDrugs, 24, 49, 10.2165/11319550-000000000-00000 Wilkins, 2012, Pulmonary hypertension: the science behind the disease spectrum, Eur Respir Rev, 21, 19, 10.1183/09059180.00008411 Teder, 2000, A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis, Am J Respir Cell Mol Biol, 23, 7, 10.1165/ajrcmb.23.1.f192 Callier, 2016 Blach-Olszewska, 2007, Mechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders, Neuropsychiatr Dis Treat, 3, 365 Vadalà, 2017, Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?, EPMA J, 8, 295, 10.1007/s13167-017-0101-y Segal, 2018, Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction, Cell Mol Immunol, 15, 586, 10.1038/cmi.2017.151 McKie, 2020 Agencies, 2020 Agency, 2020 Agency, 2020 Pecoits-Filho, 2016, Interactions between kidney disease and diabetes: dangerous liaisons, Diabetol Metab Syndr, 8, 50, 10.1186/s13098-016-0159-z Kenny, 2019, Heart Failure in Type 2 Diabetes Mellitus Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies, Circ Res, 124, 121, 10.1161/CIRCRESAHA.118.311371 Ye, 2019, Effects of BTK signalling in pathogenic microorganism infections, J Cell Mol Med, 23, 6522, 10.1111/jcmm.14548 2020 Boseley, 2020 Communication, F.D.S, 2020 Taylor, 2020 Kowalczyk, 2015, The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis, Arch Immunol Ther Exp (Warsz), 63, 41, 10.1007/s00005-014-0310-1 Kaffarnik, 2017, Correlation between plasma endothelin-1 levels and severity of septic liver failure quantified by maximal liver function capacity (LiMAx test). A prospective study, PLoS One, 12, e0178237, 10.1371/journal.pone.0178237 Jain, 2019, Endothelin-1 traps as a potential therapeutic tool: from diabetes to beyond?, Drug Discov Today, 24, 1937, 10.1016/j.drudis.2019.07.008 Barton, 2019, Endothelin: 30 Years From Discovery to Therapy, Hypertension, 74, 1232, 10.1161/HYPERTENSIONAHA.119.12105 Wernly, 2019, Trapping endothelin-1 to hunt down cardiovascular disease?, Drug Discov Today, 24, 2108, 10.1016/j.drudis.2019.10.007